Aclaris Therapeutics (ACRS) Return on Equity (2017 - 2025)
Historic Return on Equity for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to 1.15%.
- Aclaris Therapeutics' Return on Equity fell 8600.0% to 1.15% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.15%, marking a year-over-year decrease of 8600.0%. This contributed to the annual value of 0.84% for FY2024, which is 3500.0% down from last year.
- Aclaris Therapeutics' Return on Equity amounted to 1.15% in Q3 2025, which was down 8600.0% from 1.0% recorded in Q2 2025.
- In the past 5 years, Aclaris Therapeutics' Return on Equity registered a high of 0.27% during Q2 2021, and its lowest value of 1.15% during Q3 2025.
- Its 5-year average for Return on Equity is 0.56%, with a median of 0.43% in 2021.
- Per our database at Business Quant, Aclaris Therapeutics' Return on Equity skyrocketed by 4200bps in 2024 and then plummeted by -8600bps in 2025.
- Aclaris Therapeutics' Return on Equity (Quarter) stood at 0.43% in 2021, then rose by 1bps to 0.43% in 2022, then crashed by -38bps to 0.59% in 2023, then tumbled by -58bps to 0.94% in 2024, then fell by -23bps to 1.15% in 2025.
- Its Return on Equity stands at 1.15% for Q3 2025, versus 1.0% for Q2 2025 and 0.89% for Q1 2025.